We studied 2,144 adult volunteers with a self-reported diagnosis of CD who completed a baseline survey that included demographics, CD status, and an affective-cognitive index of depression. Linear and logistic regression analyses were used to determine whether CD status at 12 months was associated with the baseline measure of depression. Analyses were adjusted for confounders including age, gender, race, baseline disease activity, disease duration, prior hospitalization and surgery, corticosteroid and anti-TNF use, medication adherence, body mass index, current smoking, education, and sleep quality.
INTRODUCTION
Crohn's disease (CD) is a chronic bowel condition aff ecting >700,000 people in North America ( 1 ) . CD is characterized by episodes of exacerbations and remissions. Because the course is unpredictable and there is no cure disease management must focus on achieving and maintaining remission, preventing complications, improving quality of life, and minimizing the impact of comorbid conditions. Th e rates of depression among CD patients appear to be higher ( 2 ) than the general population. Th e key question is whether depression infl uences the manifestation and severity of CD or whether depression is a consequence of suff ering from a debilitating chronic disease. Th erefore, the aim of this study was to determine whether there is a relationship between depressive symptoms and subsequent CD activity.
Earlier cohort studies reporting comorbidity of CD and patients' mood used depression measures that include physical symptoms that overlap with those seen in CD such as disordered sleep, fatigue, and poor appetite ( 3, 4 ) . To eliminate the overlap and avoid the possibility of spurious relationships between measures of exposure and outcome, this study restricts the ascertainment of depression to one dimension of depression-aff ective-cognitive symptoms. It is yet unclear which symptom dimensions of depression are associated with CD activity, and this will be the fi rst study with adult CD patients of the relationship between a specifi c symptom dimension of depression and later CD activity. Diff erent subsets of depressive Association Between Affective-Cognitive Symptoms of Depression and Exacerbation of Crohn's Disease symptoms have been investigated with adolescents with IBD ( 5 ) . Th e principal hypothesis for this study is that CD patients experiencing aff ective-cognitive symptoms of depression at baseline were more likely to report active CD 12 months later. A secondary hypothesis is that CD patients experiencing aff ective-cognitive symptoms of depression at baseline will have more frequent hospitalizations, surgeries, and anti-TNF (anti-tumor necrosis factor) usage to treat their CD because of a more severe or a persistently active CD.
METHODS

Study population
Subjects were volunteers in CCFA Partners , an internet-based cohort study sponsored by the Crohn's and Colitis Foundation of America (CCFA). Th is cohort has been described in detail in previous publications ( 6 ) . In brief, CCFA Partners is a longitudinal Internet-based cohort of volunteers with self-reported infl ammatory bowel disease. Participants had been invited to participate in the cohort through the CCFA e-mail roster, social media, and at educational events. During the fi rst recruitment, volunteers were excluded if they were under the age of 18 years and those who did not have self-reported IBD (CD, UC, or indeterminate colitis). Volunteers also had to have Internet access to join the e-cohort and complete the surveys. Th ere were no other exclusion criteria for participation. All volunteers completed a baseline survey comprising demographics and information about their IBD. Optional modules on various patient-reported outcomes were included with the baseline survey. Volunteers were invited to complete a follow-up questionnaire every 6 months to report disease activity, changes in the treatment, and repeated measures of patientreported outcomes. Th e study protocol was approved by the Institutional Review Board at the University of North Carolina, Chapel Hill, NC, and Vanderbilt University, Nashville, TN.
Instruments
For this study, all volunteers completed a depression symptom questionnaire (PROMIS) ( 7 ) that measured exposure and a CD symptom questionnaire (SCDAI) ( 8 ) at baseline and 12 months later that measured outcome.
Depression was measured by using the National Institutes of Health Patient Reported Outcomes Measurement Information Systems (PROMIS) depression 4-item short form ( 7 ) . In validation studies, the PROMIS depression test bank items correlated with the Center for Epidemiological Studies Depression Scale, r =0.83. Th e PROMIS depression questionnaire used in this study did not include items assessing somatic symptoms that overlap with symptoms of CD such as poor sleep, fatigue, and lack of appetite. Th e short form was composed of four Likert-type fi ve-point items measuring the frequency of negative mood (I felt depressed) and cognition: negative beliefs about the self (I felt worthless, I felt helpless) and decreased life engagement/negativity to the future (I felt hopeless) during the previous 7 days. It was administered at baseline and follow-up. All responses were summed to form a raw score ranging from 4 to 20, which was then converted to a standardized score ( t -score). For all PROMIS measures, the t -score for the standardizing population is 50 with a standard deviation equal to 10. Th us, a t -score change from 55 to 65 represents a change from 0.5 standard deviations to 1.5 standard deviations above the standardizing population mean.
Disease activity at baseline and the 12-month follow-up was assessed by the Short Crohn's Disease Activity Index (SCDAI) ( 8 ) . Disease activity was modeled as both a continuous SCDAI t -score and a binary outcome with active disease being defi ned as a SCDAI t -score >150. Th e SCDAI was developed to provide a shortened and a simplifi ed Crohn's Disease Activity Index (CDAI) using a patient's self-report. We considered any abdominal surgeries within 12 months, any hospitalizations within 12 months, and the use of antiTNFs at 12 months as secondary outcomes because these medical interventions are oft en associated with greater CD activity.
Covariates
On the basis of the research literature, the following variables were included in the regression models as potential confounders of the association between depression and CD activity: age, gender, race, baseline SCDAI, disease duration, anti-TNF use, body mass index, current smoking, level of educational attainment, and sleep ( 9 ) . For the anti-TNF outcome, we also adjusted for baseline anti-TNF usage. Post hoc analyses were conducted where we additionally adjusted for baseline history of hospitalization/surgery, use of steroids, and adherence to oral medications ( 10 ) to confi rm our fi ndings.
Statistical analysis
Continuous variables were summarized using the median, 25th, and 75th percentile, and categorical variables were summarized using percentages in each category. Th e Kruskal-Wallis test (continuous variables) and Pearson's χ 2 tests (categorical variables) were used to compare baseline covariates by depression t -score quartile.
In this prospective cohort study, we represented baseline disease activity as continuous instead of as a dichotomized variable-active vs. inactive-as advocated by methodologists ( 11, 12 ) . Use of baseline disease activity as a continuous variable allowed us to operate without any assumptions about the shape of the relationship, use all the information about disease activity at hand, and allowed us to detect any non-linearity in the relation between exposure (depressive symptoms) and outcome (CD activity).
Linear regression was used to model continuous outcomes, and logistic regression was used to model binary outcomes. From the linear regression models, we report the adjusted expected change in mean SCDAI at 12 months per 10-point increase in baseline depression. From the logistic regression models, we report the odds ratio for having active disease (defi ned as SCDAI>150) per 10-point increase in the baseline depression t -score. We pre-specifi ed that depression would be fl exibly modeled as a continuous predictor while making minimal assumptions about the form of the relationship between depression symptoms and the outcome. Th is was accomplished by modeling depression using a restricted spline (3 d.f.).
On the basis of the results of the linear regression analysis of SCDAI, we found that the slope for the depression t -score changed at 55-being fl atter below 55 and steeper above 55. We report our results from all regression models in reference to 10-point changes in the depression t -score using intervals of 45-55, 55-65, and 65-75. Statistical signifi cance of the depression construct was assessed using 2 d.f. Wald tests to simultaneously test each of the depression coeffi cients were included in the regression model. Sensitivity analyses were also conducted where we treated the depression t -score as a continuous variable but without using restricted cubic splines to fl exibly model the association. Logistic models were estimated with the primary and secondary outcomes. For these models, we report the unadjusted and adjusted association of a 10-point increase in the depression t -score with each outcome. Confounding was evaluated by looking for a 10% change in the estimated regression coeffi cient for the depression t -score.
RESULTS
A total of 5,707 subjects with CD completed baseline surveys, 2,144 of whom also completed a 12-month follow-up SCDAI. Volunteers without 12-month follow-up surveys were younger (median age 40 vs. 43 years), less likely to be white (92% vs. 95%), more likely to be current smokers (12% vs. 7%), less educated (65% college and above vs. 73%), and likely to be more depressed (median t -score 52.7±10.0 vs. 51.4±9.2). Th ere was no evidence that duration of diagnosis, sex, body mass index, or sleep scores diff ered between analyzed ( n =2,144) and lost to follow ( n =3,775) subjects. Table 1 shows the distribution of patient characteristics by extent above or below a depression t -score score of 50. Respondents with the most severe depressive symptoms at baseline were younger, more recently diagnosed with CD, were smokers, were heavier, and reported lower levels of educational attainment ( Table 2 ) .
Association between baseline depression and 12-month SCDAI and secondary outcomes
We found a signifi cant association between the depression t -score and the subsequent SCDAI score, controlling for baseline differences in the SCDAI score, in both unadjusted ( P <0.001) and adjusted ( P <0.001) linear regression models. Furthermore, we found this relationship to be curved with a shallower slope below 55 and a steeper slope above 55. Figure 1 depicts this association by plotting the expected SCDAI vs. the depression t -score while adjusting for other covariates by fi xing continuous covariates at their mean and categorical covariates at their mode. Adjusting for covariates, a 10-point increase in the depression t -score from 55 to 65 was associated with a 18.6-point increase in SCDAI (95% CI: 11.5-25.6). A 10-point increase in the depression t -score from 45 to 55 was only associated with a 6.9-point increase (95% CI: 2.4-11.4) in SCDAI.
Th ere was also a signifi cant association between the elevated depression t -score and the odds of reporting active CD 12 months later in both unadjusted and adjusted logistic regression models. Figure 2 summarizes the odds ratios from the adjusted models for 10-point increases in the baseline depression t -score for the primary and secondary outcomes. Because we used regression splines to fl exibly model the association between the depression t -score and each outcome a 10-point increase in the depression t -score was not constrained to be the same for all 10-point increases. In Figure 2 , we present the odds ratios associated with Overall, there was a signifi cant association between the baseline depression t -score and the odds of active CD ( P =0.001, df=2). Hospitalizations were also signifi cantly associated with the depression t -score in adjusted models ( P =0.03, df=2), and the odds ratios were similar for increases from 45 to 55, 55 to 65, and 65 to 75. Th ere was no evidence that abdominal surgeries ( P =0.34, df=2) or anti-TNF drugs ( P =0.15, df=2) were associated with the depression t -score when depression was modeled fl exibly using splines.
Supplemental analyses
Supplemental analyses were conducted to further scrutinize the conclusions from our primary model. For these analyses, we treated depression t -scores as a continuous variable but without using restricted cubic splines to fl exibly model the association. Logistic models were estimated for the primary and secondary outcomes, and we computed the unadjusted and adjusted associations of a 10-point increase in the depression t -score with each outcome. We also conducted an addition analysis where we adjusted for medication adherence scores, baseline history of hospitalization/ surgery, use of steroids, and our other previously included confounders. In the 1,285 participants for whom the medication adherence score was available, we observed similar, albeit slightly stronger, association between baseline depression and disease activity at 12 months. Th ere was also no evidence of residual confounding based on our approach utilizing a 10% change in the estimated regression coeffi cient for the depression t -score.
DISCUSSION
Depression is a common comorbidity for patients with CD ( 2 ). Depression impacts on the quality of patients' lives ( 13 ), cost of treatment ( 14 ), adherence to disease management ( 15 ) , and may even alter the biologic potential for controlling the status of the disease ( 16 ) . Hence, we hypothesized that comorbid depressive symptoms in adults with CD would predict higher levels of CD activity a year later. We tested this hypothesis prospectively using validated measures of depressive symptoms (exposure) and CD activity (outcome). Controlling for confounding variables, the CD volunteers who reported higher levels of depressive symptoms had a greater odds of reporting more frequent diarrhea, pain, and reduced well-being 12 months later than less depressed CD volunteers. Further, CD volunteers with more severe depressive symptoms subsequently reported higher odds of hospitalization but not surgery or anti-TNF usage. Our study supports the fi ndings of earlier cohort studies showing that depression is associated with subsequent CD activity ( 3, 4, 17 ) , suggesting a temporal relationship between depression and subsequent CD activity. However, what is unique about this study is the fi nding that the association between depression and subsequent CD activity is stronger when there are higher levels of baseline depressive symptoms, suggesting a dose-response relationship. Heightened depression, especially the cognitive characteristic of negativity to the self and the future as studied in this study, may be a psychological condition that infl uences CD morbidity through physiological processes and indirectly via behavioral pathways. Th e health risk behaviors and psychobiological changes associated with depression increase the risk for chronic medical disorders, and biological changes and complications associated with chronic medical disorders may precipitate depressive episodes ( 18 ) . For example, the CD volunteers who reported greatest negativity to the self and the future and sadness at baseline were also more likely to be smokers who were overweight and less educated. Controlling for these factors attenuated the eff ect estimates, but they remained signifi cant. More needs to be known about depressed mood and negativity toward the self and the future in terms of associated eating patterns, medication use, and adherence and physical activity in order to understand how the aff ective-cognitive dimension of depression infl uences health risk behavior and the immune system of depressed CD volunteers. Depression and its symptom anti-TNF, anti-tumor necrosis factor; CI, confi dence interval.
Depression t -score was modeled using as a single linear term. Figure 1 . Association between the baseline depression t -score and SCDAI at 12-month follow-up with 95% confi dence interval. The depression t -score was modeled fl exibily using restricted cubic splines to allow for a curved relationship. SCDAI is estimated from a multivariable model and represents an average subject with a baseline SCDAI of 150, a sleep t -score of 50, length of diagnosis 15 years, white race, non-current smoker, 42-year old, body mass index of 26, and college education.
variable at baseline instead of the more typical dichotomization, which results in reduced power. Th is allowed for the detection of possible non-monotonic relationships between symptoms of depression and the CD activity level. Our fi ndings, therefore, provide more defi nitive data demonstrating that higher levels of aff ective-cognitive symptoms of depression are associated with subsequent increased disease activity and the need for hospitalization even aft er controlling for known confounders. Th ere are limitations that need to be acknowledged. First, we have explored the relationship of depressive symptoms and CD in a large internet-based cohort of CD patients. Th e sampling introduced volunteer self-selection, resulting in a cohort composed largely of Caucasian women who took fewer health risks and were less depressed and reported less active disease at the baseline. Th e study thus may under-represent individuals who might show the hypothesized relationship. Although the prospective study design with appropriate control for a number of potential confounders provides a high degree of internal validity, attrition was extremely high in this study with a loss to follow-up of 62%. Analysis of the diff erences between those CD volunteers who completed the 12-month follow-up SCDAI and those who did not demonstrated that the non-responders had a higher t -score on the depression measure. However, this diff erence in the mean t -scores was only 1.3, which, although signifi cant, is below the threshold of a dimensions are now being investigated in depressed chronic disease patients with myocardial infarction ( 19 ) and diabetes ( 20 ) . For example, study of the eff ects of depressive symptoms on immunological parameters in heart failure patients ( 21 ) showed that the level of cognitive/aff ective depression at baseline was positively associated with hsCRP (high sensitivity C reactive protein), sTNFR1, and sTNFR2 (TNF soluble receptors) at 12-month follow-up, whereas somatic/aff ective depression at baseline was positively associated with sTNFR1 and sTNFR2.
Although there is consistency in the fi ndings across the limited number of cohort studies of CD and comorbid depression, the previous studies were conducted under very diff erent conditions. Our study had methodological advantages from prior investigations. Our cohort study was not limited to a tertiary referral center and is the fi rst to our knowledge to eliminate the infl uence of overlapping somatic symptoms of depression and CD on the results. In previous cohort studies of comorbid CD and depression, depression was treated as a homogenous construct without regard to the varied symptoms of depression ( 3, 4, 17 ) . It is possible that these earlier cohort studies of depression and CD may have demonstrated correlation because the somatic symptoms of depression may be more strongly linked to the mechanisms thought to underlie the depression-CD relationship ( 22 , 23 ) . Another advantage of the present study was the use of CD activity level as a continuous 
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Symptoms of Depression and Crohn's Disease minimal important diff erence for this measure. In addition, in using the four-item PROMIS abbreviated depression scale, we did not allow a direct comparison of diff erent symptom dimensions of depression including aff ective-cognitive and aff ective-somatic symptoms in the prediction of the subsequent CD activity level. Although we do not know whether the CD volunteers had been treated with antidepressant medication or psychotherapy, in reality, that information is not relevant to the association between aff ective-cognitive depressive symptoms and the SCDAI. Finally, the SCDAI is a patient-reported measure of disease symptoms, rather than a direct measure of intestinal infl ammation. Hence, we cannot fully evaluate a direct causal relationship between symptoms of depression and increased mucosal infl ammation.
As such, we encourage future research on comorbid depression and CD activity using measures of infl ammation to help elucidate the full impact of depressive symptoms on infl ammatory processes. However, given the recently increasing interest in patientreported outcomes research, our results contribute to improved understanding of the role of depression in predicting which patients may be more likely to experience symptoms of increased CD activity.
Although the use of the study's longitudinal design suggests that aff ective-cognitive symptoms of depression are antecedent to CD activity 12 months later, both CD and depressive symptoms have potentially long induction periods, making it diffi cult to establish the precise period "at risk". Th is raises possible concern about reverse causality, with earlier CD activity infl uencing the incidence of depressive symptoms rather than the converse. In order to clarify the sequencing of depressive symptoms and CD activity and understand their dynamic interaction, longitudinal panel data will be helpful. Measures of depression (exposure) must include both cognitive and somatic symptoms of depression and their interaction over time. Crohn's disease activity (outcome) must be measured by objective methods such as fecal calprotectin and from patients' symptom appraisals and for longer periods and with shorter exposure-outcome intervals before coming to valid conclusions about the temporal relationship between CD activity and symptom dimensions of depression.
Th e present study expands and informs the fi eld in two very important ways. Th e fi rst is that it suggests that CD patients who also have aff ective-cognitive symptoms of depression are more likely to have more severe CD symptoms later in time. Th e second is that it starts to chart the map for future research about comorbid depression and CD, starting with the examination of possible reverse causality, the assessment of measurement invariance, and possible health behavior and immunological mediators of the relationship of depressive symptoms and CD activity. In the present time, however, even without complete understanding of causality or mechanism, this observation about comorbid depression and subsequent CD activity and hospitalizations makes a strong case for routine assessment of depression when evaluating and treating CD. Depressive symptoms comorbid with CD seem to add to the cost of treatment and are associated with lower quality of life and poorer clinical outcomes. Management of depression should be integral to the management of CD patients.
Negativity to the self and the future and depressed aff ect as measured here may represent adaptational diffi culties that could infl uence self-management, the immune system, and ultimately disease progression ( 20 ) . Given the substantial challenges that result from exacerbations of CD, gastroenterologists need to be alert to depression in CD patients and refer for appropriate management.
ACKNOWLEDGMENTS
Drs Stephen Entman and Robert Levine were helpful in discussing the data and in preparing the manuscript and Tara Duffi e in the submittal process.
CONFLICT OF INTEREST
Guarantor of the article : Lawrence S. Gaines, PhD. Specifi c author contributions : Study concept and design: Lawrence S. Gaines; acquisition of data: Robert S. Sandler, Millie D. Long, Michael D. Kappelman, and Christopher F. Martin; draft ing of the manuscript: Lawrence S. Gaines; statistical analysis: James C. Slaughter and Li Wang. All authors performed the analysis and interpretation of the data, and critical revision of the manuscript for important intellectual content. Lawrence S. Gaines and James C. Slaughter had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Financial support: Th is research was supported, in part, by awards from the National Center for Advancing Translational Science/ National Institute of Health (NO. UL1TR000445), Crohn's and Colitis Foundation of America, and the National Institutes of Health (P30 DK034967). Potential competing interests: None.
DISCLAIMER
Th e CCFA, National Center for Advancing Translational Science, and the NIH had no role in the design, analysis and interpretation of the data, or the preparation, review, or approval of the manuscript.
Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Rates of depression among Crohn's disease (CD) patients are higher than the general population. 
WHAT IS NEW HERE
✓ Affective-cognitive symptoms of depression predicted subsequent CD activity and hospitalization rate, suggesting a temporal relationship.
✓ CD activity is greater with baseline higher levels of affective-cognitive symptoms, suggesting a dose-response relationship.
✓ Symptom dimensions of depression may be important in understanding the association of depression and selfreported CD activity.
